Disclaimer: I also know the people behind this company.
I think there needs to be some separation between Chemeq and Recce. Yes Graham was behind both, and yes the tech is along a similar line...however that is where the similarity ends.
The new antibiotic (synthetic) is for intended to be trialled for human use.
Production efficiency is improved immensely (factors of 50 and 100)
The need for huge expensive production facilities isn't really relevant at this point, nor do I really see it being a factor going forward. If they pass these initial trials, I can't see the next raising being a huge issue, given the market cap will likely be many multiples of the proposed cap at IPO, making dilution much less a concern. If successful, I see this being partnered out/bought out long before we need to be considering production facilities.
Graham's age is definitely a consideration, however the team has other members who are well and truly versed in how the tech works and the chemistry behind it. In my opinion, the upside is well and truly worth any risks in these regards, and is why I will be invested in RCE for the longer term.
RCE Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)